Published in J Pharmacol Exp Ther on July 19, 2006
Hydrogen sulfide as a gasotransmitter. J Neurochem (2010) 2.30
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol (2010) 1.34
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol (2012) 1.19
Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol (2010) 1.14
Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal (2011) 1.13
Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications. Chem Commun (Camb) (2014) 1.03
The endogenous hydrogen sulfide producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome. Mol Pain (2009) 1.02
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One (2013) 0.99
TRPA1 has a key role in the somatic pro-nociceptive actions of hydrogen sulfide. PLoS One (2012) 0.92
Treatment with exogenous hydrogen sulfide attenuates hyperoxia-induced acute lung injury in mice. Eur J Appl Physiol (2013) 0.90
Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients. J Am Soc Nephrol (2014) 0.87
The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Med Gas Res (2015) 0.87
Endogenous hydrogen sulfide is an anti-inflammatory molecule in dextran sodium sulfate-induced colitis in mice. Dig Dis Sci (2010) 0.87
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. Mol Pain (2010) 0.85
NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res Perspect (2015) 0.85
Building a better aspirin: gaseous solutions to a century-old problem. Br J Pharmacol (2007) 0.85
Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res (2009) 0.80
Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury. Oxid Med Cell Longev (2015) 0.78
The hydrogen sulfide donor, Lawesson's reagent, prevents alendronate-induced gastric damage in rats. Braz J Med Biol Res (2013) 0.77
Toward More GI-Friendly Anti-Inflammatory Medications. Curr Treat Options Gastroenterol (2015) 0.76
Biological thiols-triggered hydrogen sulfide releasing microfibers for tissue engineering applications. Acta Biomater (2015) 0.75
International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev (2017) 0.75
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther (2005) 2.18
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol (2008) 2.15
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol (2004) 1.80
Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol (2010) 1.78
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol (2009) 1.69
Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem (2010) 1.63
Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc Natl Acad Sci U S A (2005) 1.62
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology (2006) 1.59
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol (2013) 1.56
Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol (2012) 1.53
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc Natl Acad Sci U S A (2009) 1.46
Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol (2006) 1.46
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 1.45
Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci (2003) 1.43
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology (2004) 1.42
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
Integrating role of T antigen, Rb2/p130, CTCF and BORIS in mediating non-canonical endoplasmic reticulum-dependent death pathways triggered by chronic ER stress in mouse medulloblastoma. Cell Cycle (2012) 1.41
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol (2010) 1.34
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A (2003) 1.32
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A (2009) 1.29
Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol (2008) 1.26
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res (2009) 1.23
Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem (2006) 1.21
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol (2008) 1.19
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem (2010) 1.18
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene (2003) 1.17
PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol (2006) 1.17
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15